Another important effect of semaglutide is that it can help reduce appetite
GLP-1 agonists, such as ROSE-010, relieve pain in IBS patients by altering gut motility (43), lowering inflammation (44), modulating neurotransmitters (45), reducing visceral hypersensitivity (46), and interacting with the gut microbiota (47)
Termed sarcopenic obesity, it is characterised by the concurrent decline in muscle mass and function along with increased levels of adipose tissue and is associated with higher risk of disability, metabolic dysfunction, comorbidities, e.g., T2D, chronic kidney disease, cardiovascular disease, and all-cause mortality [2, 3]
Lu Y, Ding Q, Xu X, Spatz ES, Dreyer RP, D'Onofrio G, Caulfield M, Nasir K, Spertus JA, Krumholz HM
This study and this one give a partial list of people who have unusually low levels of glutathione
This section explores potential areas of future research that could enhance the efficacy and tolerability of Semaglutide
